Alaunos Therapeutics surges after Velaris acquisition and $350 million financing

By: Quiver PriceTracker

Posted: 3 hours ago / Oct. 13, 2026 2:52 p.m. UTC

TCRT

Alaunos Therapeutics (TCRT) is up 67.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied to Alaunos announcing the acquisition of Velaris Therapeutics alongside an oversubscribed $350 million private placement, a dramatic change in scale for a microcap biotech. Investors also seem to be reacting to the company’s new cardiopulmonary pipeline and the statement that the financing is expected to fund operations into 2029.

Details:

Alaunos said on October 13 that it completed the acquisition of privately held Velaris Therapeutics, adding a pipeline aimed at pulmonary arterial hypertension and related cardiopulmonary diseases.

The same announcement said a concurrent private placement raised about $350 million in gross proceeds and should support operations into 2029, with proof-of-concept data for lead program VLR199 targeted for 2028.

The company said the transaction would leave about 358.59 million common shares outstanding on an as-converted basis, showing the deal is transformational but also highly dilutive.

This could also be because TCRT had been an extremely small-cap, thinly capitalized company; an October 5 SEC filing disclosed a Nasdaq delisting notice tied to the minimum stockholders’ equity requirement, so the financing may be viewed as easing a major balance-sheet overhang.

Sources:

Alaunos, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TCRT Hedge Fund Activity

We have seen 10 institutional investors add shares of $TCRT stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

HRT FINANCIAL LP removed 13,327 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $30,119
TWO SIGMA INVESTMENTS, LP removed 10,839 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $24,496
XTX TOPCO LTD removed 10,174 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,993
GEODE CAPITAL MANAGEMENT, LLC removed 3,204 shares (-14.2%) from their portfolio in Q2 2026, for an estimated $7,241
UBS GROUP AG removed 1,282 shares (-56.4%) from their portfolio in Q2 2026, for an estimated $2,897
ARAX ADVISORY PARTNERS added 1,216 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,748
WELLS FARGO & COMPANY/MN added 198 shares (+104.2%) to their portfolio in Q2 2026, for an estimated $447

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.